A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
iOnctura
Merck Sharp & Dohme LLC
HC Biopharma Inc.
Abramson Cancer Center at Penn Medicine
Cullinan Therapeutics Inc.
National Cancer Institute (NCI)
Amgen
Memorial Sloan Kettering Cancer Center
BeiGene
Merck Sharp & Dohme LLC
University of Chicago
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Augusta University
Augusta University
Eli Lilly and Company
Baylor College of Medicine
Aduro Biotech, Inc.
Incyte Corporation
Bayer
Mayo Clinic
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Masonic Cancer Center, University of Minnesota
Memorial Sloan Kettering Cancer Center
Virginia Commonwealth University
M.D. Anderson Cancer Center
University of Southern California
Children's Oncology Group
National Cancer Institute (NCI)
The University of Texas Health Science Center at San Antonio
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
AstraZeneca
Pfizer